Sharon Townson Sells 6,000 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Sharon Townson sold 6,000 shares of Monte Rosa Therapeutics stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $23.31, for a total value of $139,860.00. Following the sale, the insider owned 67,845 shares of the company’s stock, valued at approximately $1,581,466.95. This represents a 8.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sharon Townson also recently made the following trade(s):

• On Tuesday, June 23rd, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $60,000.00.
• On Wednesday, June 17th, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $19.00, for a total transaction of $57,000.00.

Monte Rosa Therapeutics Stock Down 1.4%

NASDAQ GLUE opened at $24.06 on Thursday. The stock has a market capitalization of $2.03 billion, a PE ratio of -16.26 and a beta of 1.56. Monte Rosa Therapeutics, Inc. has a 12-month low of $4.12 and a 12-month high of $25.77. The company has a 50 day moving average price of $19.62 and a two-hundred day moving average price of $19.04.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The business had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. As a group, equities analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp increased its stake in shares of Monte Rosa Therapeutics by 148.9% in the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after purchasing an additional 1,260,707 shares during the period. MPM Bioimpact LLC acquired a new position in shares of Monte Rosa Therapeutics during the 4th quarter worth about $18,399,000. AQR Capital Management LLC boosted its stake in Monte Rosa Therapeutics by 459.4% during the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after purchasing an additional 1,054,406 shares during the period. Braidwell LP acquired a new stake in Monte Rosa Therapeutics in the 4th quarter valued at approximately $14,870,000. Finally, Vestal Point Capital LP bought a new position in Monte Rosa Therapeutics in the 3rd quarter worth approximately $5,928,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on GLUE. Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Wells Fargo & Company lowered their price objective on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. JPMorgan Chase & Co. raised their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Guggenheim boosted their target price on Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Monte Rosa Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $33.33.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.